BPC-157 and Cancer: A Survivor's Med-Spa Case and What's Known

Complete guide: BPC-157 and TB-500: a complete guide to evidence and safety

What happened: from a “glow” ad to a recurrence

Paige Gordon of Santa Cruz, California, was diagnosed with breast cancer about two and a half years ago and, after surgery, showed no evidence of disease, according to an NBC Bay Area investigation published November 5, 2026 and updated November 6¹. In January she saw an ad for “Glow Stack,” an injectable mix containing BPC-157 that promised glowing skin. Instead of clicking the ad, she contacted a licensed nurse she knew, whose Aptos med spa she had visited for years. “I thought it must be above board, must be legit because she's selling it,” she said¹.

PSM, which published its own account on November 13, adds the details a clinician cares about: the blend, called GLOW, combines GHK-Cu, BPC-157 and TB-500; the patient was handed a sealed envelope by staff, with a vial and no instructions; no one reviewed her health history or discussed risks; the nurse texted her to inject daily, although GLOW was meant for five days a week; and the spa's website called its treatments legal and “pharmacy grade,” a term PSM says has no clear standard².

About six weeks in, Gordon read that scientists had raised concerns BPC-157 might promote tumor growth. According to PSM she switched to GHK-Cu alone, but the next vial still listed BPC-157; in August her cancer returned². Both outlets are careful: NBC says there is “no conclusive evidence” BPC-157 contributed, and PSM says there is no evidence it caused the recurrence and that Gordon does not claim it did¹². Gordon sums it up: “I'm always going to wonder”¹.

BPC-157, angiogenesis and cancer: what the evidence says

The mechanism behind the worry is well known. A 2017 study in the Journal of Molecular Medicine showed BPC-157 increased vessel density in the chick chorioallantoic membrane and in endothelial tube-formation assays, sped blood-flow recovery in ischemic rat muscle, and activated the VEGFR2-Akt-eNOS pathway¹⁰. A 2025 University of Utah review confirms that pathway and concludes that, despite broad preclinical support, BPC-157 should be considered investigational¹¹. Angiogenesis is welcome in a poorly vascularized tendon; in a person with a cancer history it is exactly the property that calls for caution.

The concern did not start at a med spa. STAT reported in February that a review by Polish researchers cautioned that new blood vessels could accelerate cancer by carrying extra oxygen to tumors⁴¹². The same report notes that almost all BPC-157 data come from a single group in Croatia: the vast majority of roughly 200 PubMed studies include Predrag Sikiric or a colleague, which reviewers tie to a risk of confirmation bias⁴. A 2026 review of unregulated injectable peptides lists “pathological angiogenesis” and “carcinogenesis” among the potential risks of BPC-157 and TB-500¹⁸.

TB-500 and thymosin β4 add nuance. TB-500 contains an acetylated fragment (residues 17-23) of human thymosin β4, not the full protein¹⁶. What is known about cancer comes from the full protein in tumor tissue: in 70 breast carcinomas, thymosin β4 overexpression correlated with lymph-node metastasis and with induction of HIF-α and VEGF-A¹⁴, and a review describes β-thymosins as participants in cell migration and metastasis¹⁵. These are correlative data on endogenous expression; they do not show an injected fragment behaves the same way, but they do not let anyone rule it out either.

On the human side, the data are minimal. A retrospective study of 17 patients with knee pain²⁰ and an intravenous infusion in two healthy adults¹⁹ are small; only the second reports no adverse effects, and neither was designed to detect tumors. STAT notes that Edwin Lee's clinical studies, the authors of both, range from two to 16 participants and lack comparison groups⁴.

What the HHS policy changed, and what it did not

On October 28 HHS announced an enforcement-discretion policy for six peptides; the notice was published in the Federal Register on October 30 (FR Doc. 2026-22192, docket HHS-OASH-2026-0496) and comments closed November 13¹⁷. It covers only 503A pharmacies, does not bind state pharmacy or medical boards or attorneys general, and is interim and subject to revision. Conditions include a valid certificate of analysis, a manufacturer registered under section 510 with its location on the COA, and MedWatch reporting⁷. For the full context, see the HHS six-peptide policy and the first sale under that policy.

BPC-157's status calls for precision. NBC reports it sat in FDA Category 2, for substances with potential significant safety risks, from September 2023 to April 22, 2026¹. FDA announced on April 15 the removal of 12 substances from that category because their nominators withdrew the nominations⁶. FDA's current page lists BPC-157 among substances “nominated but withdrawn,” cites a risk of immunogenicity for certain routes, complexities with peptide-related impurities and API characterization, and no or only limited safety information; that page does not mention carcinogenic potential or Category 2 dates⁵. NBC's statement that FDA considers the data insufficient to determine carcinogenic potential is therefore a news summary, not a quotation from that page¹⁵.

On the lack of data, PSM's executive director, Shabbir Imber Safdar, said: “It's just not been studied in enough humans to know”¹³. A physician quoted by Healio agrees that patients may read the move as an FDA endorsement, though HHS says it is not, and notes that some of these peptides affect tissue growth and cellular aging, leaving long-term cancer questions unresolved⁸.

The med-spa gap: what nobody asked

The case is useful because it isolates a process failure, not a causal finding. According to PSM, her invoice said GLOW while her records said GHK-Cu, and she was sold BPC-157 after asking to avoid it². A report from the same group says, in a photo caption, that BPC-157 vials were obtained from a telehealth provider “with little friction”³. For a physician seeing a patient with a cancer history who uses unapproved peptides, the sources point to concrete questions:

• Which exact product, from which supplier, and since when; the label and the spa's records may not match².
• Whether the product contains BPC-157 or other peptides with an angiogenic or thymosin β4 signal, and that the published human data do not assess cancer¹¹¹⁴¹⁸.
• Whether anyone documented the cancer history before selling the product, and whether there is a channel to report adverse events to MedWatch²⁷.
• What the marketing says: “pharmacy grade” is not a defined regulatory standard².

For more context, see BPC-157: from Rogan's podcast to an FDA vote, the BPC-157 and TB-500 evidence and safety guide and the logic of the GLOW, KLOW and Wolverine blends.